
Sign up to save your podcasts
Or


All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.
By Lemonada Media4.6
34723,472 ratings
All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.

36,802 Listeners

3,541 Listeners

87,705 Listeners

32,374 Listeners

9,481 Listeners

2,863 Listeners

12,362 Listeners

8,590 Listeners

318 Listeners

5,115 Listeners

762 Listeners

601 Listeners

16,097 Listeners

10,456 Listeners

856 Listeners

3,465 Listeners

388 Listeners

243 Listeners

10,896 Listeners

88 Listeners

118 Listeners

1,893 Listeners

447 Listeners

7,047 Listeners

1,186 Listeners

6,293 Listeners

623 Listeners

87 Listeners

451 Listeners

46 Listeners

145 Listeners

67 Listeners

23 Listeners

4,516 Listeners